Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of Eosinophilic Granulomatosis With Polyangiitis

NCT06046222 is registered in ClinicalTrials.gov with NS Pharma, Inc. as lead sponsor.

NCT NCT06046222
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06046222 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Efficacy and Safety of NS-229 in the Treatment of Eosinophilic Granulomatosis With Polyangiitis
Lead sponsor
NS Pharma, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 20, 2023
Completion date
December 31, 2026
Enrollment
45 (estimated)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

churg-strauss syndrome, eosinophilic granulomatosis with polyangiitis